Document is current
Any future updates will be listed below
-
Authors
Hüttmann, Andreas
Rekowski, Jan
Müller, Stefan P.
Hertenstein, Bernd
Franzius, Christiane
Mesters, Rolf
Weckesser, Matthias
Kroschinsky, Frank
Kotzerke, Jörg
Ganser, Arnold
Bengel, Frank M.
La Rosée, Paul
Freesmeyer, Martin
Höffkes, Heinz-Gert
Hertel, Andreas
Behringer, Dirk
Prange-Krex, Gabriele
Griesshammer, Martin
Holzinger, Jens
Wilop, Stefan
Krohn, Thomas
Raghavachar, Aruna
Maschmeyer, Georg
Brink, Ingo
Schroers, Roland
Gaska, Tobias
Bernhard, Helga
Giagounidis, Aristoteles
Schütte, Jochen
Dienst, Ariane
Hautzel, Hubertus
Naumann, Ralph
Klein, Alfred
Hahn, Dennis
Pöpperl, Gabriele
Grube, Matthias
Marienhagen, Jörg
Schwarzer, Andreas
Kurch, Lars
Höhler, Thomas
Steiniger, Heike
Nückel, Holger
Südhoff, Thomas
Römer, Wolfgang
Brinkmann, Marcus
Ose, Claudia
Alashkar, Ferras
Schmitz, Christine
Dürig, Jan
Hoelzer, Dieter
Jöckel, Karl-Heinz
Klapper, Wolfram
Dührsen, Ulrich https://orcid.org/0000-0002-4034-9472
-
Funding
Funding for this research was provided by:
Amgen (None)
Deutsche Krebshilfe (107592. 110515)
Roche (None)
- License Information
-
More Information
Article History
Received: 25 November 2018
Accepted: 6 December 2018
First Online: 4 January 2019
Compliance with ethical standards
:
: Andreas Hüttmann: honoraria from Bristol-Myers Squibb, Takeda, Celgene, and Roche; travel reimbursement from Gilead and Amgen; Stefan P. Müller: institutional research funding from BTG Interventional Medicine; Frank Kroschinsky: honoraria and travel reimbursement from and consultancy for Roche, Celgene, Gilead, Pfizer, and Janssen; Paul La Rosée: honoraria and travel reimbursement from and consultancy for Roche; Martin Grieshammer: honoraria from, consultancy for, and speaker’s bureau of Roche, Amgen, AOP, Novartis, Shire, and Janssen; Georg Maschmeyer: honoraria from Gilead, Pfizer, Merck Serono, Celgene, Bristol-Myers Squibb, and Boehringer Ingelheim; consultancy for Gilead; travel reimbursement from Bristol-Myers Squibb; Ingo Brink: honoraria from Siemens and Rotop; travel reimbursement from Bayer; Tobias Gaska: institutional research funding from Roche; travel reimbursement from Ipsen; Aristoteles Giagounidis: consultancy for Celgene; Matthias Grube: consultancy for Bristol-Myers Squibb and Sanofi; Claudia Ose: institutional research funding, honoraria, and travel reimbursement from Medice Arzneimittel Pütter; Jan Dürig: honoraria from and consultancy for Roche and Amgen; Wolfram Klapper: institutional research funding from Roche, Amgen, Regeneron, Novartis, and Takeda; Ulrich Dührsen: institutional research funding and honoraria from Roche and Amgen.
